<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00677144</url>
  </required_header>
  <id_info>
    <org_study_id>HMC-HO-GI-0712</org_study_id>
    <nct_id>NCT00677144</nct_id>
  </id_info>
  <brief_title>Oxaliplatin and S-1 (OS) Versus Oxaliplatin and Capecitabine (XELOX) for Advanced Colorectal Cancer</brief_title>
  <official_title>A Randomized Phase II Study of Oxaliplatin and S-1 (OS) Versus Oxaliplatin and Capecitabine (XELOX) in Patients With Advanced or Recurrent Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hallym University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hallym University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare the activity and safety of Oxaliplatin and S-1 (OS) and&#xD;
      Oxaliplatin and Capecitabine (XELOX) in patients with advance or recurrent colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Oxaliplatin and oral fluoropyrimidines (capecitabine or S-1) are active agents for colorectal&#xD;
      cancer. Recent a phase II trial of combination chemotherapy of oxaliplatin with S-1 (OS) and&#xD;
      several phase II trial of combination chemotherapy of oxaliplatin with capecitabine (XELOX)&#xD;
      demonstrated good activity and mild toxicity in advanced colorectal cancer. Oxaliplatin and&#xD;
      S-1 or capecitabine have distinct mechanisms of action and no overlap of key toxicities.&#xD;
      Furthermore, oxaliplatin and fluorouracil were shown to be highly synergistic, not only in&#xD;
      preclinical models but also in subsequent clinical trials.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall response rate</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety, time to progression, and overall survival</measure>
    <time_frame>4.6 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Colorectal Neoplasm</condition>
  <arm_group>
    <arm_group_label>OS (oxalipaltin+S-1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OS (oxaliplatin + S-1): Oxaliplatin 130mg/m2 IV on D1 every 21 days and S-1 80mg/m2/day PO [BSA &lt;1.25 40mg bid (total 80mg/day); BSA ≥1.25 - &lt;1.5 50mg bid (total 100mg/day); BSA ≥1.5 60mg bid (total 120mg/day)], divided by two on D1-14 every 21 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>XELOX (oxalipaltin+capecitabine)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>XELOX (oxalipaltin+capecitabine): Oxaliplatin 130mg/m2 IV on D1 every 21 days and Capecitabine 2000mg/m2/day PO, divided by two on D1-14 every 21 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OS (oxalipaltin+S-1)</intervention_name>
    <description>Oxaliplatin 130mg/m2 IV on D1 every 21 days and S-1 80mg/m2/day PO [BSA &lt;1.25 40mg bid (total 80mg/day); BSA ≥1.25 - &lt;1.5 50mg bid (total 100mg/day); BSA ≥1.5 60mg bid (total 120mg/day)], divided by two on D1-14 every 21 days</description>
    <arm_group_label>OS (oxalipaltin+S-1)</arm_group_label>
    <other_name>Eloxatin</other_name>
    <other_name>TS-1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XELOX (oxalipaltin+capecitabine)</intervention_name>
    <description>Oxaliplatin 130mg/m2 IV on D1 every 21 days and Capecitabine 2000mg/m2/day PO, divided by two on D1-14 every 21 days</description>
    <arm_group_label>XELOX (oxalipaltin+capecitabine)</arm_group_label>
    <other_name>Eloxatin</other_name>
    <other_name>Xeloda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed colorectal adenocarcinoma, initially diagnosed or recurred&#xD;
&#xD;
          -  Unresectable, locally advanced or metastatic&#xD;
&#xD;
          -  At least one uni-dimensional measurable lesion by RECIST criteria&#xD;
&#xD;
          -  Age 18 to 75 years old&#xD;
&#xD;
          -  Estimated life expectancy ≥3 months&#xD;
&#xD;
          -  ECOG performance status ≤2&#xD;
&#xD;
          -  Adequate bone marrow function (WBCs ≥ 4,000/µL or absolute neutrophil count ≥&#xD;
             1,500/µL, platelets ≥ 100,000/µL)&#xD;
&#xD;
          -  Adequate kidney function (creatinine &lt; 1.5 mg/dL)&#xD;
&#xD;
          -  Adequate liver function (bilirubin &lt; 2.0 mg/dL, transaminase levels &lt;2.5 times the&#xD;
             upper normal limit)&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other tumor type than adenocarcinoma&#xD;
&#xD;
          -  Previous history of chemotherapy (exception : neoadjuvant or adjuvant chemotherapy&#xD;
             without oxaliplatin)&#xD;
&#xD;
          -  Presence of CNS metastasis, psychosis, or seizure&#xD;
&#xD;
          -  Obvious bowel obstruction&#xD;
&#xD;
          -  Evidence of serious gastrointestinal bleeding&#xD;
&#xD;
          -  Past or concurrent history of neoplasm other than colorectal adenocarcinoma, except&#xD;
             for curatively treated non-melanoma skin cancer or in situ carcinoma of the cervix&#xD;
             uteri&#xD;
&#xD;
          -  Pregnant or lactating women, women of childbearing potential not employing adequate&#xD;
             contraception&#xD;
&#xD;
          -  Other serious illness or medical conditions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dae Young Zang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hallym University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hallym University Medical Center</name>
      <address>
        <city>Anyang</city>
        <zip>431-070</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <study_first_submitted>May 7, 2008</study_first_submitted>
  <study_first_submitted_qc>May 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2008</study_first_posted>
  <last_update_submitted>October 4, 2012</last_update_submitted>
  <last_update_submitted_qc>October 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 5, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colorectal Neoplasm</keyword>
  <keyword>S-1</keyword>
  <keyword>Capecitabine</keyword>
  <keyword>Oxaliplatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

